Search This Blog

Thursday, November 7, 2019

Eiger BioPharmaceuticals EPS in-line

Eiger BioPharmaceuticals (NASDAQ:EIGR): Q3 GAAP EPS of -$0.76 in-line.
Cash, cash equivalents, and short-term investments of $109.9M.
Press Release
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)